1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-Q/A
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 1999
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from __________ to __________
Commission file number: 005-52501
WARNER CHILCOTT PUBLIC LIMITED COMPANY
(Exact name of registrant as specified in its charter)
Ireland N/A
(State or other jurisdiction of incorporation (I.R.S. Employer
or organization) Identification No.)
Lincoln House, Lincoln Place, Dublin 2, Ireland
(Address of principal executive offices)
353 1 662-4962
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes [X] No [ ]
Indicate the number of shares outstanding of each of the issuer's
classes of common stock, as of the latest practicable date.
American Depositary Shares, representing Ordinary Shares, par value $.05 each;
Ordinary Shares, par value $.05 each; 12,390,730 Ordinary Shares outstanding at
March 31, 2000.
2
WARNER CHILCOTT PUBLIC LIMITED COMPANY
Table of Contents
Page No.
Item 6. Exhibits and Reports on Form 8-K 3
Signatures 4
2
3
Item 6. Exhibits and Reports on Form 8-K
a. The following exhibits were filed as follows:
Exhibit No. Description
10.1 Asset Purchase Agreement between Warner
Chilcott, Inc. and Medicis Pharmaceutical
Corporation, dated September 14, 1999(1)
27 Financial Data Schedule(2)
b. Reports on Form 8-K:
No report was filed during the three months ended September
30, 1999.
(1) This exhibit is being refiled with this amendment. Confidential material
has been omitted from this exhibit and filed separately with the SEC pursuant to
a request for confidential treatment.
(2) This exhibit was filed with the Form 10-Q on November 9, 1999.
3
4
Pursuant to the requirements of the Securities Exchange Act of 1934, this report
has been signed below by the following persons on behalf of the registrant and
in the capacities and on the dates indicated.
WARNER CHILCOTT PUBLIC LIMITED COMPANY
(Registrant)
April 27, 2000 /s/ Paul S. Herendeen
-----------------
Paul S. Herendeen
Executive Vice President &
Chief Financial Officer
(Principal Financial Officer)
April 27, 2000 /s/ David G. Kelly
-----------------
David G. Kelly
Group Vice President, Finance
(Principal Accounting Officer)
4